Olfactory Ensheathing Cell Transplantation Into Spinal Cord Prolongs the Survival of Mutant SOD1G93A ALS Rats Through Neuroprotection and Remyelination

Anatomical Record

Volumn 294, Issue 5, 2011, Pages 847-857

  Li, Ying ^a,b   Bao, Jianling ^a,c   Khatibi, Nikan H ^d   Chen, Lin ^a,b,e   Wang, Hongmei ^a   Duan, Yaokui ^b   Huang, Hongyun ^a,b,e   Zhou, Changman ^f  

^a Beijing Hongtianji Neuroscience Academy   (China)

^b TAISHAN MEDICAL UNIVERSITY   (China)

^c Medical Laboratory Center   (China)

^d LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^e Beijing Rehabilitation Center   (China)

^f PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Amyotrophic lateral sclerosis; Neuroprotection; Olfactory ensheathing cells; Remyelination; SOD1G93A rats

Indexed keywords

CHOLINE ACETYLTRANSFERASE; COPPER ZINC SUPEROXIDE DISMUTASE; GREEN FLUORESCENT PROTEIN; MYELIN BASIC PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL COUNT; CELL TRANSPLANTATION; CONTROLLED STUDY; DISEASE DURATION; EXPERIMENTAL TEST; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL NECROSIS; NEUROFILAMENT; NEUROPROTECTION; NONHUMAN; OLFACTORY ENSHEATHING CELL; PRIORITY JOURNAL; RAT; REMYELINIZATION; SPINAL CORD MOTONEURON; SPINAL CORD VENTRAL HORN; SURVIVAL; SURVIVAL TIME; THORACIC SPINAL CORD; WESTERN BLOTTING; WILD TYPE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; MALE; MOTOR NEURONS; MUTATION; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; OLFACTORY BULB; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD INJURIES; SUPEROXIDE DISMUTASE; SURVIVAL RATE;

RATTUS;

EID: 79954525282     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.21362     Document Type: Article

References (44)

1. Alexianu ME. 1995. The role of immune processes in amyotrophic lateral sclerosis pathogenesis. Rom J Neurol Psychiatry 33: 215-227.
2. Berger MM, Kopp N, Vital C, Redl B, Aymard M, Lina B. 2000. Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS. Neurology 54: 20-25.
3. Bianco JI, Perry C, Harkin DG, Mackay-Sim A, Feron F. 2004. Neurotrophin 3 promotes purification and proliferation of olfactory ensheathing cells from human nose. Glia 45: 111-123.
4. Borchelt DR. 2006. Amyotrophic lateral sclerosis-are microglia killing motor neurons? N Engl J Med 355: 1611-1613.
5. Chen C, Hu Q, Yan J, Lei J, Qin L, Shi X, Luan L, Yang L, Wang K, Han J, Nanda A, Zhou C. 2007. Multiple effects of 2ME2 and D609 on the cortical expression of HIF-1alpha and apoptotic genes in a middle cerebral artery occlusion-induced focal ischemia rat model. J Neurochem 102: 1831-1841.
6. Cleveland DW, Liu J. 2000. Oxidation versus aggregation-how do SOD1 mutants cause ALS? Nat Med 6: 1320-1321.
7. Cleveland DW, Rothstein JD. 2001. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2: 806-819.
8. Ferrero I, Mazzini L, Rustichelli D, Gunetti M, Mareschi K, Testa L, Nasuelli N, Oggioni GD, Fagioli F. 2008. Bone marrow mesenchymal stem cells from healthy donors and sporadic amyotrophic lateral sclerosis patients. Cell Transplant 17: 255-266.
9. Franssen EH, de Bree FM, Verhaagen J. 2007. Olfactory ensheathing glia: their contribution to primary olfactory nervous system regeneration and their regenerative potential following transplantation into the injured spinal cord. Brain Res Rev 56: 236-258.
10. Gajewski CD, Lin MT, Cudkowicz ME, Beal MF, Manfredi G. 2003. Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in rho(0) cells. Exp Neurol 179: 229-235.
11. Garbuzova-Davis S, Sanberg PR. 2009. Feasibility of cell therapy for amyotrophic lateral sclerosis. Exp Neurol 216: 3-6.
12. Guatteo E, Carunchio I, Pieri M, Albo F, Canu N, Mercuri NB, Zona C. 2007. Altered calcium homeostasis in motor neurons following AMPA receptor but not voltage-dependent calcium channels' activation in a genetic model of amyotrophic lateral sclerosis. Neurobiol Dis 28: 90-100.
13. Herbik MA, Chrapusta SJ, Kowalczyk A, Grieb P. 2006. Maintenance of the rat transgenic model of familial amyotrophic lateral sclerosis expressing human SOD1G93A mutation. Folia Neuropathol 44: 149-153.
14. Huang H, Chen L, Wang H, Xi H, Gou C, Zhang J, Zhang F, Liu Y. 2006a. Safety of fetal olfactory ensheathing cell transplantation in patients with chronic spinal cord injury. A 38-month follow-up with MRI. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 20: 439-443.
15. Huang H, Chen L, Wang H, Xiu B, Li B, Wang R, Zhang J, Zhang F, Gu Z, Li Y, Song Y, Hao W, Pang S, Sun J. 2003. Influence of patients' age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury. Chin Med J (Engl) 116: 1488-1491.
16. Huang H, Chen L, Xi H, Wang H, Zhang J, Zhang F, Liu Y. 2008. Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study. Clin Transplant 22: 710-718.
17. Huang H, Wang H, Chen L, Gu Z, Zhang J, Zhang F, Song Y, Li Y, Tan K, Liu Y, Xi H. 2006b. Influence factors for functional improvement after olfactory ensheathing cell transplantation for chronic spinal cord injury. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 20: 434-438.
18. Julien JP. 2001. Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. Cell 104: 581-591.
19. Lankford KL, Sasaki M, Radtke C, Kocsis JD. 2008. Olfactory ensheathing cells exhibit unique migratory, phagocytic, and myelinating properties in the X-irradiated spinal cord not shared by Schwann cells. Glia 15:1664-1678.
20. LaMonte BH, Wallace KE, Holloway BA, Shelly SS, Ascano J, Tokito M, Van WT, Howland DS, Holzbaur EL. 2002. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 34: 715-727.
21. Lepore AC, Maragakis NJ. 2007. Targeted stem cell transplantation strategies in ALS. Neurochem Int 50: 966-975.
22. Li Y, Field PM, Raisman G. 1997. Repair of adult rat corticospinal tract by transplants of olfactory ensheathing cells. Science 277: 2000-2002.
23. Lipson AC, Widenfalk J, Lindqvist E, Ebendal T, Olson L. 2003. Neurotrophic properties of olfactory ensheathing glia. Exp Neurol 180: 167-171.
24. Llado J, Haenggeli C, Pardo A, Wong V, Benson L, Coccia C, Rothstein JD, Shefner JM, Maragakis NJ. 2006. Degeneration of respiratory motor neurons in the SOD1 G93A transgenic rat model of ALS. Neurobiol Dis 21: 110-118.
25. Ludolph AC, Meyer T, Riepe MW. 2000. The role of excitotoxicity in ALS-what is the evidence? J Neurol 247 (Suppl 1): I7-I16.
26. Mazzini L, Mareschi K, Ferrero I, Vassallo E, Oliveri G, Nasuelli N, Oggioni GD, Testa L, Fagioli F. 2008. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci 265: 78-83.
27. Morita E, Watanabe Y, Ishimoto M, Nakano T, Kitayama M, Yasui K, Fukada Y, Doi K, Karunaratne A, Murrell WG, Sutharsan R, Mackay-Sim A, Hata Y, Nakashima K. 2008. A novel cell transplantation protocol and its application to an ALS mouse model. Exp Neurol 213: 431-438.
28. Qureshi M, Schoenfeld DA, Paliwal Y, Shui A, Cudkowicz ME. 2009. The natural history of ALS is changing: improved survival. Amyotroph Lateral Scler. 2009 Jun 1:1-8. [Epub ahead of print]
29. Ramon-Cueto A, Avila J. 1998. Olfactory ensheathing glia: properties and function. Brain Res Bull 46: 175-187.
30. Ramon-Cueto A, Nieto-Sampedro M. 1994. Regeneration into the spinal cord of transected dorsal root axons is promoted by ensheathing glia transplants. Exp Neurol 127: 232-244.
31. Ross CA, Poirier MA. 2004. Protein aggregation and neurodegenerative disease. Nat Med 10 (Suppl): S10-S17.
32. Roy S, Zhang B, Lee VM, Trojanowski JQ. 2005. Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol 109: 5-13.
33. Saarma M, Sariola H. 1999. Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF). Microsc Res Tech 45: 292-302.
34. Sasaki M, Black JA, Lankford KL, Tokuno HA, Waxman SG, Kocsis JD. 2006. Molecular reconstruction of nodes of Ranvier after remyelination by transplanted olfactory ensheathing cells in the demyelinated spinal cord. J Neurosci 26: 1803-1812.
35. Sasaki M, Lankford KL, Zemedkun M, Kocsis JD. 2004. Identified olfactory ensheathing cells transplanted into the transected dorsal funiculus bridge the lesion and form myelin. J Neurosci 24: 8485-8493.
36. Schmidt ER, Pasterkamp RJ, van den Berg LH. 2009. Axon guidance proteins: novel therapeutic targets for ALS? Prog Neurobiol 88: 286-301.
37. Staines DR. 2008. Are multiple sclerosis and amyotrophic lateral sclerosis autoimmune disorders of endogenous vasoactive neuropeptides? Med Hypotheses 70: 413-418.
38. Su Z, Yuan Y, Chen J, Cao L, Zhu Y, Gao L, Qiu Y, He C. 2009. Reactive astrocytes in glial scar attract olfactory ensheathing cells migration by secreted TNF-alpha in spinal cord lesion of rat. PLoS One 4: e8141.
39. Turner BJ, Parkinson NJ, Davies KE, Talbot K. 2009. Survival motor neuron deficiency enhances progression in an amyotrophic lateral sclerosis mouse model. Neurobiol Dis 34: 511-517.
40. 2+ buffering in hypoglossal motoneurons of mutant SOD1 (G93A) mice. Neurosci Lett 445: 224-228.
41. Watanabe M, Dykes-Hoberg M, Culotta VC, Price DL, Wong PC, Rothstein JD. 2001. Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 8: 933-941.
42. Weishaupt JH, Bartels C, Polking E, Dietrich J, Rohde G, Poeggeler B, Mertens N, Sperling S, Bohn M, Huther G, Schneider A, Bach A, Siren AL, Hardeland R, Bahr M, Nave KA, Ehrenreich H. 2006. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 41: 313-323.
43. Woodhall E, West AK, Chuah MI. 2001. Cultured olfactory ensheathing cells express nerve growth factor, brain-derived neurotrophic factor, glia cell line-derived neurotrophic factor and their receptors. Brain Res Mol Brain Res 88: 203-213.
44. Yan J, Chen C, Lei J, Yang L, Wang K, Liu J, Zhou C. 2006. 2-Methoxyestradiol reduces cerebral vasospasm after 48 hours of experimental subarachnoid hemorrhage in rats. Exp Neurol 202: 348-356.